The association between cognition and histamine-2 receptor antagonists in African Americans

Journal of the American Geriatrics Society

Volumn 55, Issue 8, 2007, Pages 1248-1253

  Boustani, Malaz ^a,b,c   Hall, Kathleen S ^c   Lane, Kathleen A ^c   Aljadhey, Hisham ^d   Gao, Sujuan ^c,e   Unverzagt, Frederick ^c   Murray, Michael D ^b,d   Ogunniyi, Adesola ^f   Hendrie, Hugh ^a,b,c  

^a INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Cognitive impairment; Histamine antagonists; Risk factor

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; RANITIDINE;

AFRICAN AMERICAN; AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; FEMALE; HUMAN; INCIDENCE; INTERVIEW; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; OBSERVATIONAL STUDY; UNITED STATES;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; LONGITUDINAL STUDIES; MALE;

EID: 34547133717     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01270.x     Document Type: Article

References (30)

1. Boustani M, Peterson B, Hanson L et al. Screening for dementia in primary care: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003 138 : 927 937.
2. Schubert C, Boustani M, Fox C et al. Medical comorbidity profile of dementia patients in primary care: Are they sicker? J Am Geriatr Soc 2006 54 : 104 109.
3. Sloane PD, Zimmerman S, Suchindran C et al. The public health impact of Alzheimer's disease, 2000-2050: Potential implication of treatment advances. Annu Rev Public Health 2002 23 : 213 231.
4. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002 162 : 2269 2276.
5. Nielsen TM, Somani SK, Cooper SL et al. Acid-peptic disease drug-use review in six long-term care facilities. Consult Pharm 1994 9 : 1417 1426.
6. Jacobson BC, Ferris TG, Shea TL et al. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003 98 : 51 58.
7. Top 300 Prescriptions for 2005 [on-line]. Available at. Accessed on September 30, 2006.
8. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999 15 : 15 28.
9. Breitner JC, Welsh KA, Helms MJ et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995 16 : 523 530.
10. Launer LJ, Jama JW, Ott A et al. H2 blocking drugs and the risk for Alzheimer's disease: The Rotterdam Study. Neurobiol Aging 1997 18 : 257 259.
11. Anthony JC, Breitner JC, Zandi PP et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County Study. Neurology 2000 54 : 2066 2071.
12. Zandi PP, Anthony JC, Hayden KM et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 2002 59 : 880 886.
13. Hanlon JT, Landerman LR, Artz MB et al. Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly. Pharmacoepidemiol Drug Saf 2004 13 : 781 787.
14. Carlson MC, Tschanz JT, Norton MC et al. H2 histamine receptor blockade in the treatment of Alzheimer disease: A randomized, double-blind, placebo-controlled trial of nizatidine. Alzheimer Dis Assoc Disord 2002 16 : 24 30.
15. Murray MD, Lane KA, Gao S et al. Preservation of cognitive function with antihypertensive medications: A longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002 162 : 2090 2096.
16. Unverzagt FW, Gao S, Baiyewu O et al. Prevalence of cognitive impairment: Data from the Indianapolis study of health and aging. Neurology 2001 57 : 1655 1662.
17. Hendrie HC, Ogunniyi A, Hall KS et al. Incidence of dementia and Alzheimer's disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001 285 : 739 747.
18. Hendrie HC, Osuntokun BO, Hall KS et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 1995 152 : 1485 1492.
19. Hall KS, Hendrie HC. CSI"D" and culture fair cognitive testing. In : Copeland J, Abou-Saleh M, Blazer D, eds. Principles and Practice of Geriatric Psychiatry, 2nd Ed. Sussex, England : John Wiley & Sons Ltd, 2000.
20. Morris JC, Mohs RC, Rogers H et al. Consortium to establish a registry for Alzheimer's disease (CERAD): Clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988 24 : 641 652.
21. Unverzagt FW, Hall KS, Torke AM et al. Effects of age, education, and gender on CERAD neuropsychological test performance in an African American sample. Clin Neuropsychol 1996 10 : 180 190.
22. Hendrie HC, Lane KA, Ogunniyi A et al. The development of a semi-structured home interview (CHIF) to directly assess function in cognitively impaired elderly people in two cultures. Int Psychogeriatr 2006 18 : 653 666.
23. World Health Organization. ICD-10. The International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland: World Health Organization; 1992. Report No.: V. 3, 1992.
24. Diagnostic and Statistical Manual of Mental Disorders, Revised 3rd Ed. Washington, DC : American Psychiatric Association, 1987.
25. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the department of health and human services task force on Alzheimer's disease. Neurology 1984 34 : 939 944.
26. Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991 114 : 1027 1034.
27. Eisendrath SJ, Ostroff JW. Ranitidine-associated delirium. Psychosomatics 1990 31 : 98 100.
28. Das AF, Freston JW, Jacobs J et al. An evaluation of safety in 37,252 patients treated with cimetidine or ranitidine. Gastroenterology 1990 11 : 127 149.
29. Slugg PH, Haug MT III., Pippenger CE. Ranitidine pharmacokinetics and adverse central nervous system reactions. Arch Intern Med 1992 152 : 2325 2329.
30. Ruscin JM, Page RL, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 2002 36 : 812 816.